{"id":"doi:10.1186/s40364-021-00315-7","kind":"review","title":"Targeting neoantigens for cancer immunotherapy","authors":["Xuan Zhao","Xiaoxin Pan","Yi Wang","Yi Zhang"],"author_count":4,"year":2021,"published":"2021-07-28","venue":"Biomarker Research","cited_by":78,"doi":"10.1186/s40364-021-00315-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s40364-021-00315-7","archive_url":"https://space-kitty.com/papers/doi:10.1186/s40364-021-00315-7","updated":null,"pmid":"34321091","pmcid":null,"openalex_id":"W3184105584","pdf_url":"https://biomarkerres.biomedcentral.com/counter/pdf/10.1186/s40364-021-00315-7","abstract":"Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generation sequencing and utilization of machine-learning algorithms, it has become feasible to computationally predict neoantigens by depicting genetic alterations, aberrant post-transcriptional mRNA processing and abnormal mRNA translation events within tumor tissues. Consequently, neoantigen-based therapies such as cancer vaccines have been widely tested in clinical trials and have demonstrated promising safety and efficacy, opening a new era for cancer immunotherapy. We systematically summarize recent advances in the identification of both personalized and public neoantigens, neoantigen formulations and neoantigen-based clinical trials in this review. Moreover, we discuss future techniques and strategies for neoantigen-based cancer treatment either as a monotherapy or as a combination therapy with radiotherapy, chemotherapy or immune checkpoint inhibitors.","abstract_license":"CC-BY (publisher license, via OpenAlex)","license":"cc-by","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Cancer Immunotherapy and Biomarkers"],"details":null,"provenance":"openalex","attribution":"Abstract of \"Targeting neoantigens for cancer immunotherapy\" by Xuan Zhao, Xiaoxin Pan, Yi Wang et al., https://doi.org/10.1186/s40364-021-00315-7, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}